Dalia Kaakour, MD

Articles by Dalia Kaakour, MD

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

January 27th 2024

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Dr Kaakour on the Rationale For Evaluating Genomic Testing Patterns in Prostate Cancer

ByDalia Kaakour, MD

January 26th 2024

Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.

Dalia Kaakour, MD

Articles by Dalia Kaakour, MD

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

Dr Kaakour on the Rationale For Evaluating Genomic Testing Patterns in Prostate Cancer

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma